Hyaluronic Acid (HA) Technologies
Search documents
Anika Therapeutics Touts $3B TAM, Cingal & Hyalofast Growth Plans at Canaccord MSK Conference
Yahoo Finance· 2026-03-03 08:29
Griffin framed the company’s overall opportunity set as a total addressable market (TAM) of more than $3 billion, and provided TAM estimates for several categories:Griffin also referenced recent results, stating the company “just announced” its results last week, including positive EBITDA and positive free cash flow in 2025. He said Anika generated about $5 million of adjusted EBITDA and more than $11 million of operating cash flow in 2025.Griffin said Anika has operated for 33 years with a primary focus on ...